Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Net (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Receivables - Net data on record, last reported at $366.2 million in Q4 2025.

  • For Q4 2025, Receivables - Net rose 38.24% year-over-year to $366.2 million; the TTM value through Dec 2025 reached $366.2 million, up 38.24%, while the annual FY2025 figure was $366.2 million, 38.24% up from the prior year.
  • Receivables - Net reached $366.2 million in Q4 2025 per APLS's latest filing, up from $345.5 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $366.2 million in Q4 2025 and bottomed at $719000.0 in Q2 2021.
  • Average Receivables - Net over 5 years is $149.4 million, with a median of $169.3 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: skyrocketed 2571.15% in 2023, then fell 29.66% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $10.1 million in 2021, then dropped by 23.52% to $7.7 million in 2022, then surged by 2571.15% to $206.4 million in 2023, then grew by 28.36% to $264.9 million in 2024, then soared by 38.24% to $366.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $366.2 million in Q4 2025, $345.5 million in Q3 2025, and $214.1 million in Q2 2025.